Q-omics provides the consensus-scored TMEM99 profile across patient tissues and cancer cell-line models. TMEM99 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM99 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TMEM99 RNA expression shows 17,349 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, THCA, and ACC as cancer lineages where TMEM99 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM99 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM99 survival associations across molecular data types. TMEM99 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM99 RNA expression–survival associations across cancer types. High TMEM99 expression shows unfavorable associations in KIRP, KICH, HNSC and LUAD, but favorable associations in LUSC and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM99 RNA expression.
This table summarizes TMEM99 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM99. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM99 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, LUAD, LUSC and HNSC. The THCA box plot shows higher TMEM99 RNA expression in normal versus tumor tissue (log2 FC = −1.012, t-test p < 0.001).
This table shows molecular features associated with TMEM99 in patient tissues and cancer cell lines. In patient samples, TMEM99 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM99 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
